Compare Alcon AG (ALC) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Canadian Natural Resources Ltd. — how do they compare? Alcon AG trades at $73.8 (market cap $36.44B), while Canadian Natural Resources Ltd. trades at $47.95 (market cap $98.11B). The key difference: Canadian Natural Resources Ltd. is far larger — about 2.7× Alcon AG's market cap, and Canadian Natural Resources Ltd. pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| ALC | CNQ | |
|---|---|---|
Market Cap | $36.44B | $98.11B |
Sector | Health | Energy |
52-Week High | $90.12 | $50.55 |
52-Week Low | $62.02 | $29.31 |
Enterprise Value | $40.28B | $108.54B |
Dividend Yield | 0.48% | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.
The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.
Canadian Natural Resources (CNQ) trades at $47.845, up 1.26% today, with a bullish technical signal and strong earnings momentum after Q2 2026 EPS beat estimates. The company shows robust profitability with a 22.87% net margin and 26.69% ROE, supported by record production and disciplined capital spending. Recent news highlights dividend reliability and operational strength, with analyst consensus heavily favoring buy ratings.
CNQ presents a compelling investment case with attractive valuation (P/E 11.82), consistent dividend payouts, and positive cash flow trends. Key risks include oil price volatility and rising debt levels, but the company's scale and efficiency underpin resilience. Wall Street optimism, with 27 buy ratings, suggests further upside potential amid stable energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
